[A23-66] Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V

Last updated 21.12.2023

Project no.:

Commission awarded on 30.06.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy

Result of dossier assessment:
  • If high-dose therapy is an option: added benefit not proven
  • If high-dose therapy is not an option: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2023-12-21 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form